Unaudited Financial Result for the quarter ended on June 30, 2026 along with Limited Review Report thereon.

STARSOURCE MULTITRADE LIMITED (Formerly known as Chemo Pharma Laboratories Limited) (CIN: L46900MH1942PLC003556) Date: August 14, 2026 Bombay Stock Exchange Limited Department of Corporate Services, 25th Floor, P. J. Towers, Dalal Street, Mumbai-400001 Script Id: 506365 ISIN: INE320M01019 Subject: Outcome of Board Meeting held on August 14, 2026. Dear Sir / Madam, Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Friday, August 14, 2026 at the Registered Office of the Company, inter alia, have considered and approved Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2026. In this regard, we are enclosing herewith: 1. Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2026, along with Limited Review Report thereon. 2. Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid information will also be available on website of the company. The meeting commenced at 03:30 PM and concluded at 04:05 PM. The same may please be taken on record. Thanking You. Yours Faithfully, FOR Starsource Multitrade Limited (Formerly known as Chemo Pharma Laboratories Limited) RUCHIT MEHTA Managing Director & Chief Executive Officer DIN: 08810586 Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad– 380005, India Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294 Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com STARSOURCE MULTITRADE LIMITED (Formerly known as Chemo Pharma Laboratories Limited) Reg Office:- 5, Kumud Apartment CHS Ltd, Karnik Road Chikan Ghar, Kalyan, Thane, KALYAN,Maharashtra, 421301 CIN: L46900MH1942PLC003556 Email: chemopharmalaboratorieslimited@gmail.com, Website: www.starsourcemultitrade.com STATEMENT OF STANDALONE Un-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (Rs. In Thousands, except EPS) Quarter Ended Year ended Sr. (Standalone) (Standalone) Particulars No. 30-Jun-26 31-Mar-26 30-Jun-25 31-Mar-26 Un-Audited Audited Un-Audited Audited 1 (a) Net Sales/Income from operations 745.85 0.00 0.00 5,256.56 (b) Other Income 0.00 8.72 207.12 238.86 Total Income (a+b) 745.85 8 .72 207.12 5 ,495.42 2 Expenditure (a) Cost of Material Consumed 0.00 0.00 0.00 0.00 (b) Purchase of Stock in Trade 0.00 0.00 0.00 3 ,765.35 (c) Changes in inventories 0.00 0.00 0.00 0.00 (d) Employee Benefit Expense 288.00 216.00 240.60 888.60 (e) Finance Cost 0.31 0.00 5.38 9.81 (f) Depreciation & Amortization Expense 1.35 3.48 0.00 3.48 (g) Other Expenses 246.35 502.20 1,18,011.79 1,19,377.10 Total Expenditure (a+b+c+d+e+f+g) 5 36.01 7 21.69 1 ,18,257.77 1 ,24,044.34 3 Profit before Exceptional Items & Tax (1-2) 209.84 (712.97) (1,18,050.65) (1,18,548.92) 4 Exceptional Items 0.00 0.00 0.00 5 Profit before Tax (3-4) 209.84 (712.97) (1,18,050.65) (1,18,548.92) 6 Tax Expenses Current Tax i) Income Tax related to current year 0.00 0.00 0.00 0.00 ii) Income Tax of earlier years 0.00 0.00 0.00 0.00 iii) Deferred Tax (Assets)/Liabilities 0.00 0.80 0.00 0.80 iv) MAT Credit Entitlement 0.00 0.00 0.00 0.00 7 Profit/(loss)aftertaxfortheperiod(beforeadjustment 209.84 (713.77) (1,18,050.65) (1,18,549.72) for Associate) (5-6) 8 Add : Share of (Profit)/Loss of Associate 0.00 0.00 0.00 0.00 9 ProfitforthePeriod(afteradjustmentforAssociate(7+ 209.84 (713.77) (1,18,050.65) (1,18,549.72) 10 Other Comprehensive Income (OCI) (a)Itemsnottobereclassifiedsubsequentlytoprofitand 0.00 0.00 0.00 0.00 loss (b) Items to be reclassified subsequently to profit and 0.00 0.00 0.00 0.00 loss ('c) Income Tax Related to Item not to be reclassify 0.00 0.00 0.00 0.00 (d) Income Tax Related to Item to be reclassify 0.00 0.00 0.00 0.00 11 Total Comprehensive Income (9+10) 209.84 (713.77) (1,18,050.65) (1,18,549.72) 12 Paid up Equity Share Capital 15,000.00 15,000.00 15,000.00 15,000.00 (Face Value Rs. 10/- each) 13 ReservesexcludingRevaluation ReservesasperBalance (2,019.16) (2,229.00) (1,604.65) (2,129.34) Sheet of previous accounting year 14 Earning Per Share (EPS) (par value of Rs. 10/- each) Basic 0.14 (0.48) (78.70) (79.03) Diluted 0.14 (0.48) (78.70) (79.03) *Not Annualised Notes 1 TheaboveauditedfinancialresultsarereviewedbytheAuditCommitteeandapprovedbytheBoardofDirectorsatits meeting held on 14th August, 2026. TheCompanyhasnoreportablebusinesssegment.Hence,separateinformationforsegmentwisedisclosureisgivenin accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required. TheseresultshavebeenpreparedinaccordancewiththeIndianAccountingStandard(referredtoas"IndAS")34- InterimFinancialReportingprescribedunderSection133oftheCompaniesAct,2013readwithCompanies(Indian Accounting Standards) Rules as amended from time to time and considering going concern aussmption. The Statutory Auditors have carried out limited review of the Unaudited Results of the Compnay for the Quarter ended June 30, 2026. 5 TheabovefinancialresultsareextractedfromtheAuditedFinancialStatementsoftheCompany,whichareprepared in accordance with the Indian Accounting Standards ('lnd As')as prescribed under section 133 of the companies Act,2013 read with relevant rules issued thereunder and considering going concern assumption. 6 The figures have been re-grouped / re-arranged / re-classified / re-worked wherever necessary to make them comparable. For Starsource Multitrade Limited Ruchit Mehta Place : Kalyan (Managing Director) Date : 14th August, 2026 DIN : 08810586 RECONCILIATON OF STANDALONE NET PROFIT FOR THE QUARTER ENDED 30th JUNE, 2026 Rs. In Thousands STANDALONE UNAUDITED UNAUDITED AUDITED PARTICULARS QUARTER QUARTER ENDED ENDED YEAR ENDED 30.06.2026 30.06.2025 31.03.2025 Reconciliation of Profit After Tax as reported earlier: Net Profit / (Loss) for the Period (as per AS) -118050.65 (1,18,050.65) ( 412.97) Benefit / (Charge): Impact of Deferred Income (Government Grant) Amortized to Income 0.00 0.00 Impact of Fair Valuation of Financial Instruments 0.00 0.00 Impact of Actuarial Gain / Loss Taken OCI 0.00 0.00 Impact of Adjustment of Deferred Tax Income 0.00 0.00 Impact of Adjustment of MAT Credit Entitlement 0.00 0.00 Net Profit / (Loss) for the Period (as per AS) (1,18,050.65) ( 412.97) For Starsource Multitrade Limited RUCHIT MEHTA Place : Kalyan MANAGING DIRECTOR Date : 14th August, 2026 DIN: 08810586 OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) - FOR THE QUARTER ENDED 30TH JUNE 2026 (In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated December 31, 2024) Sr. No Particulars Remarks B. Statement on deviation or variation for proceeds of public issue, 1 NOT APPLICABLE rights issue, preferential issue, qualified institutions placement etc. C. Format for disclosing outstanding default on loans and debt 2 NOT APPLICABLE securities D. Format for disclosure of related party transactions (applicable only 3 NOT APPLICABLE for half yearly filings i.e. , 2nd and 4th quarter) E. Statement on impact of audit qualifications (for audit report with modified opinion ) submitted along-with annual audited financial 4 NOT APPLICABLE results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter) FOR STARSOURCE MULTITRADE LIMITED Date : 14th August, 2026 RUCHIT MEHTA Place : Kalyan MD & CEO DIN: 08810586 STARSOURCE MULTITRADE LIMITED (Formerly known as Chemo Pharma Laboratories Limited) (CIN: L46900MH1942PLC003556) Date: August 14, 2026 Bombay Stock Exchange Limited Department of Corporate Services, 25th Floor, P. J. Towers, Dalal Street, Mumbai-400001 Script Id: 506365 ISIN: INE320M01019 Sub: Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing O [Showing first 8,000 characters — download PDF for full document]